The FLOT4-AIO trial compared perioperative FLOT with perioperative ECF/ECX for resectable gastric and gastro-oesophageal junction adenocarcinoma. The primary endpoint result was:
- A FLOT improved 5-year overall survival to 45% versus 36% with ECF/ECX ✓
- B FLOT improved median overall survival to 50 months versus 35 months with ECF
- C Both regimens were equally effective with better tolerability for ECF
- D FLOT had significantly higher pathological complete response rates but no survival advantage
Correct answer: A. FLOT improved 5-year overall survival to 45% versus 36% with ECF/ECX
Explanation
The FLOT4-AIO trial (Al-Batran et al.) demonstrated that perioperative FLOT (docetaxel, oxaliplatin, leucovorin, 5-FU) significantly improved overall survival compared to ECF/ECX: 5-year survival 45% vs 36%, and median OS 50 months vs 35 months. FLOT achieved higher pathological response rates (16% vs 6% pathological complete response) and replaced ECF as the standard perioperative regimen for gastric/GOJ adenocarcinoma.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.